Myrobalan News
Myrobalan Therapeutics Announces MRO-001 Selected for China’s CARE Program Extension Pilot for ALS Development
Myrobalan Therapeutics Presents Collaborative Research Featuring GPR17 Antagonist at ACTRIMS 2026
Myrobalan Therapeutics Awarded a Grant from the National Multiple Sclerosis Society to Advance Development of MRO-002 in Multiple Sclerosis
Myrobalan Therapeutics Appoints Robin Kleiman Ph.D., as Chief Scientific Officer
Myrobalan Therapeutics Strengthens Board of Directors with Appointment of Emma Reeve
Myrobalan Presents GPR17 Antagonist Preclinical Data at ECTRIMS 2024
Myrobalan Therapeutics Names Grant Bogle to Board of Directors
Co-Founder, Professor Guoping Feng (MIT/Broad) Inducted into the National Academy of Sciences
